DJIA 16,563.30 -317.06 -1.88%
NASDAQ 4,369.77 -93.13 -2.09%
S&P 500 1,930.67 -39.40 -2.00%
market minute promo

ZIOPHARM Oncology (NASDAQ: ZIOP)

3.13 -0.13 (-3.99%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

ZIOP $3.13 -3.99%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $3.18
Previous Close $3.26
Daily Range $3.11 - $3.22
52-Week Range $2.75 - $5.58
Market Cap $315.3M
P/E Ratio -5.34
Dividend (Yield) $0.00 (0.0%)
Volume 525,174
Average Daily Volume 715,209
Current FY EPS -$0.38

Sector

Healthcare

Industry

Drugs

ZIOPHARM Oncology (ZIOP) Description

ZIOPHARM Oncology Inc. is a biopharmaceutical company engaged in the development and commercialization of small molecule and synthetic biology approaches to new cancer therapies. Website: http://www.ziopharm.com/

News & Commentary

The 5 Most Hated Biotechs: Myraid, Sarepta, Questcor, Ziopharm, and MannKind

Myraid Genetics, Sarepta Therapeutics, Questcor Pharmaceuticals, Ziopharm Oncology, and MannKind top the list of the most shorted biotechs.

Ziopharm: Pipeline Expansion And Data Updates To Drive Near-Term Upside

Ziopharm Joins The CAR Crowd

ZIOPHARM Announces Expansion Of Ground-Breaking Synthetic Immuno-Oncology Programs With Intrexon And

ZIOPHARM Announces Expansion Of Ground-Breaking Synthetic Immuno-Oncology Programs With Intrexon And Clinical Program Update

Why Ziopharm Looks Worth Adding To Your Biotechnology Portfolio Pipeline

The Sirens Of Ziopharm

Can the Uptrend Continue for ZIOPHARM (ZIOP)? - Tale of the Tape

Mid-Morning Market Update: Markets Gain On Jobs Data; VeriFone Earnings Beat Estimates

Ziopharm - A Stock Worth Owning To Benefit Your Portfolio This Year And Beyond

ZIOPHARM Presents Encouraging Data - Analyst Blog

Comparison Shopping For Small-Cap Biotech Deals

See More ZIOP News...

ZIOP's Top Competitors

ZIOP $3.13 (-3.99%)
Current stock: ZIOP
AMGN $127.39 (-2.02%)
Current stock: AMGN
GILD $91.55 (-2.39%)
Current stock: GILD
BIIB $334.39 (-2.94%)
Current stock: BIIB